Physician profile
Mohan Penmetcha
NPI 1578514667
$3,081.90
in general payments reported to CMS, 2019-2025
13 companies · $22.96 in 2025
The $22.96 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $632 · 2021: $342 · 2022: $69.53 · 2025: $22.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.71 | 2019-2022 | |
| Pfizer INC. | $516.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $390.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $288.28 | 2019-2020 | |
| Ucb, INC. | $240.57 | 2019-2020 | |
| Amgen INC. | $208.12 | 2019-2022 | |
| Lilly USA, LLC | $151.60 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.07 | 2019 | |
| Janssen Biotech, INC. | $102.92 | 2019-2020 | |
| Celgene Corporation | $40.40 | 2019 | |
| Horizon Therapeutics Plc | $38.41 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Glaxosmithkline, LLC. | $15.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Penmetcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.